Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma.

Kondrashova O, Nguyen M, Shield-Artin K, Tinker AV, Teng NNH, Harrell MI, Kuiper MJ, Ho GY, Barker H, Jasin M, Prakash R, Kass EM, Sullivan MR, Brunette GJ, Bernstein KA, Coleman RL, Floquet A, Friedlander M, Kichenadasse G, O'Malley DM, Oza A, Sun J, Robillard L, Maloney L, Bowtell D, Giordano H, Wakefield MJ, Kaufmann SH, Simmons AD, Harding TC, Raponi M, McNeish IA, Swisher EM, Lin KK, Scott CL; AOCS Study Group.

Cancer Discov. 2017 Sep;7(9):984-998. doi: 10.1158/2159-8290.CD-17-0419. Epub 2017 Jun 6.

2.

Comparative microRNA profiling of sporadic and BRCA1 associated basal-like breast cancers.

Yan M, Shield-Artin K, Byrne D, Deb S, Waddell N; kConFab Investigators, kConFab, Haviv I, Fox SB.

BMC Cancer. 2015 Jul 8;15:506. doi: 10.1186/s12885-015-1522-4.

3.

Stage-specific analysis of plasma protein profiles in ovarian cancer: Difference in-gel electrophoresis analysis of pooled clinical samples.

Bailey MJ, Shield-Artin KL, Oliva K, Ayhan M, Reisman S, Rice GE.

J Carcinog. 2013 Jun 29;12:10. doi: 10.4103/1477-3163.114216. Print 2013.

4.

Enhanced RAD21 cohesin expression confers poor prognosis in BRCA2 and BRCAX, but not BRCA1 familial breast cancers.

Yan M, Xu H, Waddell N, Shield-Artin K, Haviv I; kConFab authors, McKay MJ, Fox SB.

Breast Cancer Res. 2012 Apr 26;14(2):R69.

5.

Identification of ovarian cancer-associated proteins in symptomatic women: A novel method for semi-quantitative plasma proteomics.

Shield-Artin KL, Bailey MJ, Oliva K, Liovic AK, Barker G, Dellios NL, Reisman S, Ayhan M, Rice GE.

Proteomics Clin Appl. 2012 Apr;6(3-4):170-81. doi: 10.1002/prca.201100008.

PMID:
22532453

Supplemental Content

Loading ...
Support Center